Pilot Study of Resveratrol Impact Compared with Rosuvastatin and Their Combination on Lipid Profile in Patients with Essential Hypertension

Yu.N. Sirenko, S.N. Kushnir, G.V. Ponomareva


Objective: to assess the impact of resveratrol compared with rosuvastatin and their combination on lipid profile in patients with essential hypertension and dyslipidemia.
Material and Methods. The study included 73 patients divided into two groups: I group (n = 38) at baseline received rosuvastatin 20 mg/day for a month, then resveratrol 50 mg/day has been added for a month: II group (n = 35) at the beginning of the study received resveratrol in a dose of 50 mg/day for a month, then therapy was added by rosuvastatin 20 mg/day. At the baseline and after 2 months of the study we evaluated the laboratory data: the level of total cholesterol, HDL choleste-rol, LDL cholesterol, triglycerides; we measured office blood pressure (BP), heart rate, carried out daily BP monitoring.
Results. At the end of the observation, we noted significant decrease in total cholesterol in the first group by 28.8 %, the degree of reduction (Δ) was –1.7 mmol/l, in the second group the level of total cholesterol decreased by 32.4 %, (Δ = –2.2 mmol/l). Patients who took resveratrol, regardless of the stage of treatment showed better reduction in total cholesterol. Decrease in total cholesterol was observed in both the first and second group, and the addition of a second drug potentiated cholesterol lowering effect of treatment. By the end of the observation period, we noted a significant decrease in LDL cholesterol levels in both groups
(p = 0.005/0.005): in the first group by 27 % (Δ = –1 mmol/l) versus
25 % (Δ = –0.9 mmol/l) in the second group, differences are non-significant. Reduction in LDL cholesterol was most pronounced in patients of the first group. The most beneficial effect on HDL cholesterol we noted in the second group: HDL cholesterol increased by 35.7 %
(Δ = +0.5 mmol/l) in these patients, however, this effect was achieved as a result of their significant increase after the second month of treatment with additional administration of rosuvastatin. Both in the first and in the second group, we noted a significant decrease in triglycerides, but the decrease was more pronounced in the first group after the addition of resveratrol to therapy. It should be noted that when at a smaller degree of lowering in triglyceride levels (Δ –0.4/–0.2 mmol/l in groups) and at a smaller number of patients with triglycerides higher than 1.7 mmol/l in the second group, we note the greatest reduction in the number of patients and the degree of triglycerides reduction percentage wise. We have identified a subgroup of patients T (resveratrol), with triglycerides levels higher than 1.7 mmol/l. At the end of the observation period triglycerides level decreased to 1.6 ± 0.1 mmol/l, the degree of reduction —1.2 mmol/l, percentage wise 42.9 %, and the number of patients decreased to 3 people.
Conclusions. Treatment with resveratrol in combination with rosuvastatin resulted in normalization of lipid profile in hypertensive patients with dyslipidemia. Resveratrol potentiated holesterin lowering effect of statin. Resveratrol significantly reduced the level of triglycerides in the blood, especially when it was initially elevated. Resveratrol therapy was safe, well tolerated, no adverse reactions were reported in patients over the observation period.


Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease // Lancet. — 1992. — 339. —


Koenig W., Sund M., Fröhlich M., Fischer H.G., Löwel H., Döring A., Hutchinson W.L., Pepys M.B. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 // Circulation. — 1999. — 99. — 237-242.

Bertelli A., Bertelli A.A., Gozzini A., Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity // Drugs Exp. Clin. Res. — 1998. — 24. — 133-138.

Petrovski G., Gurusamy N., Das D.K. Resveratrol in cardiovascular health and disease // Ann. N. Y. Acad. Sci. — 2011. — 1215. — 22-33.

Fujitaka K., Otani H., Jo F., Jo H., Nomura E., Iwasaki M., Nishikawa M., Iwasaka T., Das D.K. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment // Nutr. Res. — 2011. — 31. — 842-847.

Brasnyó P., Molnár G.A., Mohás M., Markó L., Laczy B., Cseh J., Mikolás E., Szijártó I.A., Mérei A., Halmai R., Mészáros L.G., Sümegi B., Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients // Br. J. Nutr. — 2011. — 106. — 383-389.

Kruithof E.K. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins // Thromb Haemost. — 2008. — 100. — 969-975.

Maruyama S., Shibata R., Ohashi K., Ohashi T., Daida H., Walsh K., Murohara T., Ouchi N. Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism // J. Biol. Chem. — 2011. — 286. — 32790-32800.

Penumathsa S.V., Thirunavukkarasu M., Koneru S., Juhasz B., Pant R., Menon V.P., Otani H., Maulik N. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat // J. Mol. Cell. Cardiol. — 2007. —

— 508-516.

Talavera J. A Double Blind, Randomized, Multicenter, Pa-rallel Group, Placebo Control Trial to Evaluate the Effect of Statin Therapy on Triglycerides Levels in Mexican Hypertriglyceridemic Patients // 59th Annual Scientific Sessions of the American College of Cardiology. — March, 2010. — Abstract 1076-112.

Saito Y., Yamada N., Shirai K., Sasaki J., Ebihara Y., Yanase T., Fox J.C. Effect of rosuvastatin 5–20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia // Atherosclerosis. — Oct. 2007. — Abstract 194(2). — 505-11. Epub. 2007 Jan 16.

Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M.J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D.; European Association for Cardiovascular Prevention and Rehabilitation, ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. — 2011. — 32. — 1769-1818.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта